Patents by Inventor Svetlana Bergelson

Svetlana Bergelson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POTENCY ASSAYS FOR VIRAL VECTOR PRODUCTION
    Publication number: 20220267798
    Abstract: The present disclosure provides sensitive and robust assays for determining the potency of payloads encoded by recombinant viral vectors. Particularly, the present disclosure provides assays to determine the potency of SMN polypeptide as expressed by recombinant viral vectors used for the treatment of spinal muscular atrophy. The present description encompasses, inter alia, methods for determining potency (e.g., biological activity), e.g., relative potency, of a recombinant viral vector.
    Type: Application
    Filed: August 7, 2020
    Publication date: August 25, 2022
    Inventors: Marina Feschenko, Svetlana Bergelson, Anthony Christophe Leyme
  • Antibody-dependent cell-mediated phagocytosis assay for reliably measuring uptake of aggregated proteins
    Patent number: 11340225
    Abstract: The present disclosure provides methods of assaying for antibody-dependent cell-mediated phagocytosis (ADCP). In some embodiments, the methods include monomerizing and labeling a protein, contacting the protein with a protein-specific antibody to form an antibody-protein complex, contacting the antibody-protein complex with a phagocytic cell to permit phagocytosis, and assessing the amount of internalized fluorescence.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: May 24, 2022
    Assignee: Biogen International Neuroscience GmbH
    Inventors: Carl Co, Allyson Masci, Svetlana Bergelson
  • ANTIBODY-DEPENDENT CELL-MEDIATED PHAGOCYTOSIS ASSAY FOR RELIABLY MEASURING UPTAKE OF AGGREGATED PROTEINS
    Publication number: 20190079077
    Abstract: The present disclosure provides methods of assaying for antibody-dependent cell-mediated phagocytosis (ADCP). In some embodiments, the methods include monomerizing and labeling a protein, contacting the protein with a protein-specific antibody to form an antibody-protein complex, contacting the antibody-protein complex with a phagocytic cell to permit phagocytosis, and assessing the amount of internalized fluorescence.
    Type: Application
    Filed: March 14, 2017
    Publication date: March 14, 2019
    Inventors: Carl Co, Allyson Masci, Svetlana Bergelson
  • Hepatitis C virus constructs characterized by high efficiency replication
    Publication number: 20050260221
    Abstract: The present invention relates to recombinant hepatitis C virus (HCV)-derived nucleic acids and to stable rapidly growing cell clones derived from human hepatoma Huh-7 cell line and supporting high titer replication of said recombinant HCV nucleic acids. The subgenomic HCV replicons and cell clones of the instant invention represent the in vitro system of choice for studies of HCV propagation, anti-viral drug screening, and vaccine development.
    Type: Application
    Filed: April 20, 2005
    Publication date: November 24, 2005
    Applicant: Anadys Pharmaceuticals, Inc.
    Inventors: Vadim Bichko, Victor Shifrin, Svetlana Bergelson
  • Hepatitis C virus constructs characterized by high efficiency replication
    Publication number: 20040005549
    Abstract: The present invention relates to recombinant hepatitis C virus (HCV)-derived nucleic acids and to stable cell clones derived from human hepatoma Huh-7 cell line supporting high titer replication of said recombinant HCV nucleic acids. The subgenomic HCV replicons and cell clones of the instant invention represent the in vitro system of choice for studies of HCV propagation, anti-viral drug screening, and vaccine development.
    Type: Application
    Filed: May 9, 2003
    Publication date: January 8, 2004
    Applicant: ANADYS PHARMACEUTICALS, INC.
    Inventors: Vadim Bichko, Victor Shifrin, Svetlana Bergelson